Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895976 | 0.88 | KMT2A (0.45) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL7466902 | 0.84 | NPC1 (0.46) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL1577179 | 0.84 | MEN1 (0.44) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL28137098 | 0.84 | MEN1 (0.44) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL1576811 | 0.81 | ALOX5 (0.46) | KMT2AMEN1NPC1RAB9ACA9 | |
| SCHEMBL6813227 | 0.81 | KMT2A (0.54) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL1576833 | 0.80 | MEN1 (0.41) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL14161731 | 0.80 | KMT2A (0.46) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL25342645 | 0.79 | EPHX1 (0.50) | KMT2AMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL25342640 | 0.79 | EPHX1 (0.50) | KMT2AMEN1ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242926-B2 | Processes for the preparation of lacosamide and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2016-01-26 | — | — | US | claimed |
| US-8853439-B2 | Processes for the preparation of lacosamide and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2014-10-07 | — | — | US | claimed |
| US-20140296572-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-10-02 | — | — | US | claimed |
| US-20120209022-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2012-08-16 | — | — | US | claimed |
| EP-2480524-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2012-08-01 | — | — | EP | claimed |
| WO-2011039781-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-04-07 | — | — | WO | claimed |
| EP-3144295-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | Divi's Laboratories Limited (IN) | 2017-03-22 | — | — | EP | disclosed |
| EP-2444390-B1 | Process for producing Lacosamide | EUTICALS GMBH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9447024-B1 | Process for the preparation of lacosamide | DIVI'S LABORATORIES LIMITED (IN) | 2016-09-20 | — | — | US | disclosed |
| US-9242926-B2 | Processes for the preparation of lacosamide and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2016-01-26 | — | — | US | disclosed |
| US-8853439-B2 | Processes for the preparation of lacosamide and intermediates thereof | CADILA HEALTHCARE LIMITED (IN) | 2014-10-07 | — | — | US | disclosed |
| US-20140296572-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-10-02 | — | — | US | disclosed |
| US-8598386-B2 | Process for producing lacosamide | EUTICALS GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20120209022-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2012-08-16 | — | — | US | disclosed |
| EP-2480524-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2012-08-01 | — | — | EP | disclosed |
| EP-2444390-A1 | Process for producing Lacosamide | Archimica GmbH (DE) | 2012-04-25 | — | — | EP | disclosed |
| US-20120095251-A1 | Process for Producing Lacosamide | EUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2011039781-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095251-A1 | Process for Producing Lacosamide | NAAA, TET3, GNMT | KMT2A 23/4885MEN1 3098/4885NPC1 4579/4885 |
| US-20120209022-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CA3, TREH, NAAA | KMT2A 494/4885MEN1 1948/4885NPC1 3639/4885 |
| US-20140296572-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CA3, TREH, NAAA | KMT2A 494/4885MEN1 1948/4885NPC1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.